Top 6 Growth Stocks For The Next 10 Years

getty

Now that high inflation has subsided and interest rates are falling, you may be looking to reposition your portfolio for growth. Let’s explore three sectors and six growth stocks that could deliver on your long-term wealth creation goals.

Why Focus On Long-Term Growth Stocks?

For patient investors, long-term growth stocks have upside. First, long holding periods minimize trading fees. Lower taxes can also result, especially with growth stocks that aren’t paying dividends.

Additionally, long holding periods are easier to manage and can encourage higher returns. Investors who aren’t timing the market don’t have to monitor and evaluate every headline. They also don’t have to feel anxious about market downturns. They can simply do nothing and wait for the market to recover.

Most importantly, long-term growth stocks can produce real wealth through compound returns. Compounding happens when stock price gains begin appreciating. The gains-on-gains phenomenon escalates growth potential over time, without further contributions.

Top Sectors For Growth Stocks In The Next Decade

Economic trends shape the future of the growth economy. Understanding those trends can help you focus your research on sectors that are most likely to expand.

Currently, the outlook is strong for technology, healthcare and energy. The Bureau of Labor Statistics is predicting high job growth in these sectors based on three expected trends:

High demand for data processing and software will support growth in technology.
An aging population and increased incidence of chronic conditions such as heart disease will expand the healthcare sector.
Rising needs for electricity to power EVs and data centers will drive energy demand, particularly for renewable sources like solar and wind.

Criteria Used For Selecting These Growth Stocks

Keeping the sector trends in mind, I identified six top growth stocks by screening U.S. public companies on these criteria:

Operating in technology, healthcare or energy sector
EPS growth greater than 20%
Sales growth greater than 10%
Five-year EPS growth outlook above 10%
Return on equity (ROE) above the company’s 10-year historic average
Buy or strong buy average rating from analysts
Debt-to-equity (DTE) ratio below 1
Market capitalization of $10 billion or greater

Combined, these qualities describe companies that have growth histories, strong outlooks, rising ROEs, manageable debt and the scale to absorb economic downturns.

To finalize the best growth stock picks, I ordered the resulting list from the highest to lowest five-year EPS growth outlook. I then selected the top two from each of the targeted sectors.

Much more than breaking news, our diverse reporting digs deeper with unparalleled insights that empower you to make better informed decisions. Become a Forbes member and unlock unlimited access to cutting-edge strategies, actionable insights, and updated analysis from our network of leading finance experts.

6 Top Growth Stocks For The Next 10 Years

The table below identifies six of the best growth stocks in technology, health care and energy. The table is followed by a discussion of each stock that summarizes the company’s business model, key metrics and relevant business developments.

Table data source: StockAnalysis.com.

For more investing ideas, see best value stocks and best stocks for 2024.

1. Dynatrace (DT)

Stock price: $55.13
Revenue growth: 22.3%
EPS growth: 154.6%
Five-year EPS outlook: 38.6%
DTE: 0.04

Dynatrace Business Overview

Dynatrace operates a subscription-based technology infrastructure platform that monitors applications and microservices, protects against security vulnerabilities, logs analytics data and automates workflows to resolve security problems quickly. Dynatrace has customers around the world in financial services, retail, government, transportation and software.

Why DT Is A Top Growth Stock Choice

Statista reports that global spending on digital transformation—which is the business adoption of new technologies to enhance efficiency—reached $1.85 trillion in 2022. That represents 16% growth from the prior year.

Enterprises undergoing digital transformation require better tools to optimize systems performance and prevent technology outages. Dynatrace is a top contender for that sizable market, which Insider Monkey has quantified at $50 billion.

In its first quarter 2025 earnings release, DT reported 20% constant-currency growth in annual recurring revenue versus the prior-year quarter. The company also increased its non-GAAP operating margin by 100 basis points to 29% and grew free cash flow by nearly 84%.

2. Nvidia (NVDA)

Stock price: $134.80
Revenue growth: 194.7%
EPS growth: 142.5%
Five-year EPS outlook: 37.4%
DTE: 0.17

Nvidia Business Overview

Nvidia provides high-performance graphics processing units (GPUs) for use in AI, autonomous driving, 5G, robotics and gaming applications. Nvidia is fabless, meaning the company outsources manufacturing to focus on design and innovation.

Why NVDA Is A Top Growth Stock Choice

Nvidia has been an incredible growth story over the last two years, rising from a split-adjusted $16 per share to nearly $140. Today, the company holds an estimated 70% to 95% market share for AI chips. That is an enviable position because Gartner projects AI chip spending will increase from $53 billion in 2023 to nearly $92 billion in 2025.

Second-quarter 2025 highlights from Nvidia, reported in August, include 154% quarter-over-quarter revenue growth in its data center division and 168% growth in diluted EPS. The data center division encompasses sales of NVDA’s AI-related solutions.

Discover more in-depth insights, entrepreneurial advice and winning strategies that can propel your journey forward and save you from making costly mistakes. Elevate your journey by becoming a Forbes member. Unlock unlimited access to premium journalism plus exclusive members-only events gathering leading business minds that shape tomorrow.

3. First Solar (FSLR)

Stock price: $211.49
Revenue growth: 25.9%
EPS growth: 78.9%
Five-year EPS outlook: 35.0%
DTE: 0.09

First Solar Business Overview

First Solar provides photovoltaic (PV) solar energy solutions in the U.S. and worldwide. The company’s thin PV modules have a lower carbon footprint than conventional crystalline silicon PV panels.

Why FSLR Is A Top Growth Stock Choice

The International Energy Agency expects solar power to deliver 80% of the growth in global renewable energy capacity between now and 2030. Rooftop solar systems plus the construction of major solar power plants will contribute. First Solar is the largest U.S. producer of solar panels, primarily serving industrial applications.

First Solar’s share price dipped in early October after two analysts lowered their price targets. The analysts from Jefferies and Bank of America held their buy ratings on FSLR but noted a few short-term headwinds. These included potential supply chain issues, labor shortages and regulatory concerns. For long-term solar investors, this pullback probably creates a buying opportunity.

First Solar’s second-quarter earnings highlights, reported in July, included 25% quarter-over-quarter revenue growth and a doubling of diluted EPS versus the prior-year quarter.

4. Boston Scientific (BSX)

Stock price: $87.10
Revenue growth: 13.7%
EPS growth: 127.1%
Five-year EPS outlook: 28.6%
DTE: 0.53

Boston Scientific Business Overview

Boston Scientific makes medical devices that diagnose and treat various conditions, including gastrointestinal disorders, coronary artery disease and some forms of cancer. Customers include hospitals, clinics, medical offices and outpatient facilities around the world.

Why BSX Is A Top Growth Stock Choice

At least four analysts have raised their price targets for BSX in recent weeks. One factor driving the excitement is Boston Scientific’s planned early presentation of its transcatheter aortic valve replacement (TAVR) data. Analysts assume the expedited release signals confidence in the results of the company’s study on its Acurate Transfemoral Aortic Valve System for TAVR.

TAVR treats the narrowing of the aortic valve less invasively than open-heart surgery. Grand View Research has predicted the global TAVR market will grow at a CAGR of 7.2% between 2024 and 2030.

Boston Scientific also recently closed on the acquisition of Silk Road Medical. The transaction is expected to be accretive to BSX’s adjusted EPS in 2026 and beyond.

In its second quarter 2024, Boston Scientific grew revenues by 14.5% and EPS by 22% from the prior-year period.

5. Medpace Holdings (MEDP)

Stock price: $347.91
Revenue growth: 21.4%
EPS growth: 33.1%
Five-year EPS outlook: 17.8%
DTE: 0.17

Medpace Holdings Business Overview

Medpace is a clinical research organization that runs clinical trials for customers in the biotech, pharma and medical device industries. Customers are primarily small to mid-sized biopharma companies that do not have the resources required to run clinical trials in-house.

Why MEDP Is A Top Growth Stock Choice

The per-share price of Medpace has pulled back more than 20% since its earnings release in July. Analysts have also lowered their price targets. The good news is that these developments are related to temporary circumstances. Analysts are primarily concerned with slow biotech funding and deal flow, plus a decline in MEDP’s bookings this year.

UBS analyst Dan Leonard, as quoted by Business Insider, believes Medpace will grow faster than peers in the long term, even if the short-term pace is dampened by poor market conditions.

In the second quarter 2024, Medpace grew revenue by 14.6%, backlog by 13.7% and diluted EPS by 42% versus the prior-year quarter.

6. Schlumberger Limited (SLB)

Stock price: $44.78
Revenue growth: 12.7%
EPS growth: 21.3%
Five-year EPS outlook: 12.8%
DTE: 0.63

Schlumberger Business Overview

Schlumberger provides technology services for the oil and gas industry. From flow-rate measurement services to exploration data processing, the company’s software and hardware solutions are designed to increase efficiency and streamline operations for oil and gas companies.

Why SLB Is A Top Growth Stock Choice

As with Medpace, analysts covering Schlumberger have lowered price targets but remain bullish on the stock long term. A question mark in the immediate term is the outlook for oil prices. Falling oil prices could lessen production, which would be a headwind for Schlumberger. Despite analysts’ reductions, the average price target on SLB still represents 42% upside.

Schlumberger recently grew quarterly revenues by 13%, adjusted Ebitda by 17% and adjusted diluted EPS by 18% versus the prior-year period.

Bottom Line

You can maximize your portfolio’s appreciation potential with growth stocks that operate within expanding economic sectors. Once you have those companies in your portfolio, stay patient and focused on the long term. Let compounding work its magic and it can deliver measurable increases in your net worth over time.